Candor on Cancer Screening
BOSTON – One of today’s most contentious medical debates centers on cancer screening, the benefits of which seem anything but debatable. Indeed, earlier detection, many believe, logically must give patients an advantage in fighting the disease. In fact, the evidence does not always support this assumption. Prostate cancer is a case in point.
Screening entails the mass testing of individuals of a certain age and gender, regardless of family history or personal health, to identify a potential disease state. For screening to be useful, the test or procedure must readily identify the disease in question, and the subsequent treatment must result in some measurable benefit. In other words, the screened population must be better off than the non-screened population.
For some health issues – such as elevated cholesterol – screening yields positive results: a simple blood test measures the amounts of good and bad cholesterol in the blood, making it easier to detect related cardiovascular disease, which could lead to heart attacks or strokes. Those who are screened, diagnosed, and treated experience a lower rate of cardiovascular events.
We hope you're enjoying Project Syndicate.
To continue reading, subscribe now.
Get unlimited access to PS premium content, including in-depth commentaries, book reviews, exclusive interviews, On Point, the Big Picture, the PS Archive, and our annual year-ahead magazine.
Already have an account or want to create one to read two commentaries for free? Log in